Ayala Pharmaceuticals Inc (fka ADXS)

[ignatiusrielly35]

Good luck with that. Clearly ADXS is not going out of its way to present prostate data at the conference that is not strong, whether it is mono or combo, or both. If only the mono is good, with not much synergy with Merck's checkpoint, then Merck should obviously still be interested in licensing PSA, because that means that its checkpoint provides little or no value to that indication. If the combo is better than the mono, same result. We only need one, but both would be ideal.